Clinical trials: Next Generation Sequencing (NGS)
Pediatric, Solid Tumors, NGS
Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors
Samples of 200 patients with pediatric malignant solid tumors will prospectively be collected. Selected samples are sufficient for next generation sequencing(NGS) and available for follow-up information.
- Trial name
- NCT05076071
- Testing
- NGS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Yizhuo Zhang
Cystic Fibrosis
Perceptions of the CF Screening Protocol Incorporating NGS
Newborn bloodspot screening (from now on referred to as screening) for cystic fibrosis (CF) became part of the national screening programme in 2007. Screening for CF is also well established internationally.
- Trial name
- NCT06299566
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- King's College London
Rare Diseases, Genetic Predisposition
Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes
For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included.
- Trial name
- EXGEFATU (NCT04731857)
- Testing
- Retrospective data analysis
- Where
- Germany
- Volunteers
- 12,000 people
- Sponsor
- University Hospital Tuebingen
Orofacial Clefts, Next Generation Sequencing (NGS)
Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping
Orofacial clefts, the most common congenital craniofacial malformations, have a complex etiology involving an interaction between genetic and environmental factors.
- Conditions
- Orofacial Clefts, Next Generation Sequencing (NGS), Optical Genome Mapping
- Trial name
- CARTOFENTE (NCT06880094)
- Testing
- blood withdrawal
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI